Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, Habu D, Tanaka T
Lancet. 2001 Jan 20;357(9251):196-7. doi: 10.1016/S0140-6736(00)03595-9.
In a prospective randomised controlled study, 90 patients with chronic active hepatitis C and compensated cirrhosis were assigned symptomatic treatment or interferon alfa (IFN-alpha). We report data on decompensation, detection of hepatocellular carcinoma, and mortality rates. IFN-alpha gave a sustained response in only a small proportion of patients, but worsening of compensated cirrhosis was prevented and development of hepatocellular carcinoma was inhibited, increasing the survival rate. The risk ratio of IFN-alpha versus symptomatic treatment decreased by 0.250 for progression to Child-Pugh grade B, 0.256 for detection of hepatocellular carcinoma, and 0.135 for a fatal outcome.
在一项前瞻性随机对照研究中，90例慢性活动性丙型肝炎合并代偿性肝硬化患者被分配接受对症治疗或干扰素α（IFN-α）治疗。我们报告了失代偿、肝细胞癌检测及死亡率的数据。IFN-α仅在一小部分患者中产生持续应答，但可预防代偿性肝硬化的恶化，并抑制肝细胞癌的发生，从而提高生存率。与对症治疗相比，IFN-α治疗使进展至Child-Pugh B级的风险比降低0.250，肝细胞癌检测的风险比降低0.256，致命结局的风险比降低0.135。
